EPRX

Eupraxia Pharms

• Dow Jones·03/13 01:23

  *Eupraxia Pharmaceuticals 4Q Loss $16.7M >EPRX.T

• Dow Jones·02/19 07:30

  *Eupraxia: Pre-Funded Warrants to Purchase Up to 1.428M Common Shares in Lieu Thereof (the 'Pre-Funded Warrants') at Price of $6.99 Each >EPRX.T

• Dow Jones·02/19 07:30

  *Eupraxia: Prices 6.428M Common Shares at a Price of $7.00 Per Common Share >EPRX.T

• Dow Jones·02/19 07:30

  *Eupraxia: Cantor and LifeSci Capital Are Joint Book-Running Managers for the Offering >EPRX.T

• Dow Jones·02/19 07:30

  *Eupraxia: Offering Expected to Close on Feb. 20 >EPRX.T

• Dow Jones·09/23/2025 16:44

  Eupraxia Pharmaceuticals Down Over 7%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk

• Dow Jones·09/23/2025 02:56

  *Eupraxia Pharmaceuticals Expects Offering to Close on Sept. 24 >EPRX.T

• Dow Jones·09/23/2025 02:56

  *Eupraxia Pharmaceuticals to Use Net Proceeds From Offering Primarily for Continued Advancement of Its Product Pipeline >EPRX.T

• Dow Jones·09/23/2025 02:56

  *Eupraxia Pharmaceuticals Prices 12.7M Public Offering Shares at US$5.50 Each >EPRX.T

• Dow Jones·09/23/2025 02:56

  *Eupraxia Pharmaceuticals Expects Gross Proceeds of Approximately US$70M From Offering >EPRX.T

• Dow Jones·09/22/2025 20:01

  *Eupraxia Pharmaceuticals: Announces Proposed Public Offering of Common Shrs

• Dow Jones·06/16/2025 15:33

  Eupraxia Pharmaceuticals Initiated at Speculative Buy by Canaccord Genuity

• Dow Jones·06/16/2025 15:33

  Eupraxia Pharmaceuticals Price Target Announced at C$9.00/Share by Canaccord Genuity

• Dow Jones·05/06/2025 22:03

  *Eupraxia Pharmaceuticals: Clinical Supplies of EP-104IAR, EP-104GI Made in the U.S. by Third-Party

• Dow Jones·05/06/2025 22:03

  *Eupraxia Pharmaceuticals: Expects to Continue to Access Manufactured Products From the U.S. >EPRX.T